{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:23:40Z","timestamp":1761488620905},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral neuropathy (PN) is a frequent complication of plasma-cell dyscrasias such as monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenstr\u00f6m's disease, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, Castleman's disease, and light-chain amyloidosis. PN can be associated with the underlying disease or it can related to the treatment. The novel immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib have changed the standard treatment of multiple myeloma. Treatment-related PN induced by thalidomide (TiPN) or bortezomib (BiPN) has become the most frequent cause of symptomatic polyneuropathy in multiple myeloma and related diseases. Dealing with PN has become a major challenge in current clinical practice for multiple myeloma patients. This review deals with practical issues such as etiology, incidence, symptoms, and clinical management of treatment-emergent PN. The major focus of the hematologist should be on the prevention of PN, primarily by frequent monitoring of the patient and by timely and adequate dose reduction of thalidomide and bortezomib. Thalidomide should not be given for periods longer than 18 months, and if it is, then patients should be carefully monitored with a low threshold for discontinuation in the face of any emergent neuropathy. In the case of BiPN, the dose of bortezomib should be reduced and\/or the administration interval should be prolonged from biweekly to weekly. Adequate pain management and supportive care require a multidisciplinary approach involving the treating physician, expert nursing staff, and a neurologist as clinically indicated.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.423","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"423-430","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Dealing with Neuropathy in Plasma-Cell Dyscrasias"],"prefix":"10.1182","volume":"2010","author":[{"given":"Pieter","family":"Sonneveld","sequence":"first","affiliation":[{"name":"Departments of Hematology and Neurology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost L.M.","family":"Jongen","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111708464616300_B1","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","article-title":"Neuropathies associated with paraproteinemia","volume":"338","author":"Ropper","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.beha.2005.01.024","article-title":"Neurological aspects of multiple myeloma and related disorders","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111708464616300_B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1188\/08.CJON.S1.29-35","article-title":"Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Tariman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"2019111708464616300_B4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00019052-199610000-00003","article-title":"Monoclonal gammopathy and neuropathy","volume":"9","author":"Notermans","year":"1996","journal-title":"Curr Opin Neurol"},{"key":"2019111708464616300_B5","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"2019111708464616300_B6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019111708464616300_B7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"2019111708464616300_B8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"2019111708464616300_B9","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111708464616300_B10","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Res"},{"key":"2019111708464616300_B11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"2019111708464616300_B12","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B13","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019111708464616300_B14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1212\/01.WNL.0000049462.03800.B1","article-title":"Thalidomide-induced neuropathy: a ganglionopathy?","volume":"60","author":"Giannini","year":"2003","journal-title":"Neurology"},{"key":"2019111708464616300_B15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"key":"2019111708464616300_B16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"key":"2019111708464616300_B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"2019111708464616300_B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"2019111708464616300_B19","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5694\/j.1326-5377.2004.tb05980.x","article-title":"Thalidomide-induced bradycardia and its management","volume":"180","author":"Coutsouvelis","year":"2004","journal-title":"Med J Aust"},{"key":"2019111708464616300_B21","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma","volume":"26","author":"Lacy","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J Pain"},{"key":"2019111708464616300_B24","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111708464616300_B26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01121.x","article-title":"A systematic review of phase II trials of thalidomide\/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma","volume":"81","author":"von Lilienfeld-Toal","year":"2008","journal-title":"Eur J Haematol"},{"key":"2019111708464616300_B27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"2019111708464616300_B29","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B30","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"2019111708464616300_B31","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2019111708464616300_B32","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","journal-title":"Blood"},{"key":"2019111708464616300_B34","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"2019111708464616300_B36","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B37","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B38","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"2019111708464616300_B39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111708464616300_B40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B41","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1557-9190(11)70492-9","article-title":"Peripheral neuropathy with VMP resolves in the majority of patients and shows a plateau [Abstract]","volume":"9","author":"Mateos","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111708464616300_B42","doi-asserted-by":"crossref","first-page":"8536a","DOI":"10.1200\/jco.2009.27.15_suppl.8536","article-title":"Lenalidomide, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study [Abstract]","volume":"27","author":"Anderson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111708464616300_B43","doi-asserted-by":"crossref","first-page":"351a","DOI":"10.1182\/blood.V114.22.351.351","article-title":"A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [Abstract]","volume":"114","author":"Cavo","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111708464616300_B44","doi-asserted-by":"crossref","first-page":"1794a","DOI":"10.1182\/blood.V114.22.1794.1794","article-title":"Genetic associations with bortezomib mediated neuropathy in multiple myeloma [Abstract]","volume":"114","author":"Corthals","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111708464616300_B45","doi-asserted-by":"crossref","first-page":"3875a","DOI":"10.1182\/blood.V114.22.3875.3875","article-title":"Pharmacogenomic (PGx) analysis of bortezomib-associated peripheral neuropathy in the phase 3 VISTA trial of bortezomib plus melphalan-prednisone versus melphalan-prednisone in multiple myeloma [Abstract]","volume":"114","author":"Ricci","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2019111708464616300_B46","doi-asserted-by":"crossref","first-page":"426a","DOI":"10.1182\/blood.V114.22.426.426","article-title":"Genetic variations associated with overall and progression-free survival in multiple myeloma patients treated with thalidomide combinations [Abstract]","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"2019111708464616300_B47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111708464616300_B48","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"2019111708464616300_B49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0609.2007.00823.x","article-title":"Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma","volume":"78","author":"Offidani","year":"2007","journal-title":"Eur J Haematol"},{"issue":"22","key":"2019111708464616300_B50","doi-asserted-by":"crossref","first-page":"3866a","DOI":"10.1182\/blood.V114.22.3866.3866","article-title":"Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study [Abstract]","volume":"114","author":"Petrucci","year":"2009","journal-title":"Blood"},{"key":"2019111708464616300_B51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"2019111708464616300_B52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1529-8027.2009.00214.x","article-title":"CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study","volume":"14","author":"CI-PERINOMS Study Group","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"2019111708464616300_B53","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"key":"2019111708464616300_B54","doi-asserted-by":"crossref","first-page":"8515a","DOI":"10.1200\/jco.2009.27.15_suppl.8515","article-title":"A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients [Abstract]","volume":"27","author":"Palumbo","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B55","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.2002.99.502","article-title":"Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid","volume":"20","author":"Gedlicka","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111708464616300_B56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3122\/jabfm.16.1.47","article-title":"Botanicals and dietary supplements in diabetic peripheral neuropathy","volume":"16","author":"Halat","year":"2003","journal-title":"J Am Board Fam Pract"},{"key":"2019111708464616300_B57","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.6004\/jnccn.2010.0115","article-title":"Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia","volume":"8","author":"Richardson","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111708464616300_B58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"2019111708464616300_B59","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2008.18.5017","article-title":"From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol","volume":"26","author":"Colvin","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/423\/1492401\/bep00110000423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/423\/1492401\/bep00110000423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T13:47:21Z","timestamp":1637156841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/423\/96016\/Dealing-with-Neuropathy-in-PlasmaCell-Dyscrasias"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.423","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}